Prostate Cancer Progression After Androgen Deprivation Therapy: Mechanisms of Castrate Resistance and Novel Therapeutic Approaches

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2013 Jun 12

PMID 23752182

Citations 420

Authors

T Karantanos

P G Corn

T C Thompson

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is the second-leading cause of cancer-related mortality in men in Western societies. Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer cells, and androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally advanced and metastatic disease. Although a majority of patients initially respond to ADT, most will eventually develop castrate resistance, defined as disease progression despite serum testosterone levels of <20 ng/dl. The recent discovery that AR signaling persists during systemic castration via intratumoral production of androgens led to the development of novel anti-androgen therapies including abiraterone acetate and enzalutamide. Although these agents effectively palliate symptoms and prolong life, metastatic castration-resistant prostate cancer remains incurable. An increased understanding of the mechanisms that underlie the pathogenesis of castrate resistance is therefore needed to develop novel therapeutic approaches for this disease. The aim of this review is to summarize the current literature on the biology and treatment of castrate-resistant prostate cancer.

Citing Articles

ARv7 promotes the escape of prostate cancer cells from androgen deprivation therapy-induced senescence by mediating the SKP2/p27 axis.

Zhuang D, Kang J, Luo H, Tian Y, Liu X, Shao C BMC Biol. 2025; 23(1):66.

PMID: 40022149 PMC: 11871636. DOI: 10.1186/s12915-025-02172-4.

Small cell lung cancer and prostate cancer cells with varying neuroendocrine differentiation markers show sensitivity to imipridone ONC201/TIC10.

Ding E, Pinho-Schwermann M, Zhang S, Purcell C, El-Deiry W Am J Transl Res. 2025; 17(1):104-115.

PMID: 39959215 PMC: 11826210. DOI: 10.62347/IBUS3598.

SNP rs9364554 Modulates Androgen Receptor Binding and Drug Response in Prostate Cancer.

Yan Y, Shi L, Ma T, Wang L, Huang H Biomolecules. 2025; 15(1).

PMID: 39858458 PMC: 11763896. DOI: 10.3390/biom15010064.

Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer.

Wolf I, Schultze-Seemann S, Gratzke C, Wolf P Antibodies (Basel). 2025; 14(1.

PMID: 39846613 PMC: 11755620. DOI: 10.3390/antib14010005.

CXCR1 Expression in MDA-PCa-2b Cell Upregulates ITM2A to Inhibit Tumor Growth.

Adekoya T, Smith N, Kothari P, Dacanay M, Li Y, Richardson R Cancers (Basel). 2025; 16(24.

PMID: 39766038 PMC: 11674668. DOI: 10.3390/cancers16244138.

References

Thompson T, Southgate J, Kitchener G, Land H . Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell. 1989; 56(6):917-30. DOI: 10.1016/0092-8674(89)90625-9. View

Steinkamp M, OMahony O, Brogley M, Rehman H, LaPensee E, Dhanasekaran S . Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res. 2009; 69(10):4434-42. PMC: 2765801. DOI: 10.1158/0008-5472.CAN-08-3605. View

Saloniemi T, Jokela H, Strauss L, Pakarinen P, Poutanen M . The diversity of sex steroid action: novel functions of hydroxysteroid (17β) dehydrogenases as revealed by genetically modified mouse models. J Endocrinol. 2011; 212(1):27-40. DOI: 10.1530/JOE-11-0315. View

Yee D . The insulin-like growth factor system as a treatment target in breast cancer. Semin Oncol. 2002; 29(3 Suppl 11):86-95. DOI: 10.1053/sonc.2002.34060. View

Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z . AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013; 17(1):113-24. PMC: 3545102. DOI: 10.1016/j.cmet.2012.12.001. View

Truica C, Byers S, Gelmann E . Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 2000; 60(17):4709-13. View

Zhu M, Kyprianou N . Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 2009; 24(3):769-77. PMC: 2830130. DOI: 10.1096/fj.09-136994. View

Jones E, Pu H, Kyprianou N . Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets. 2009; 13(2):227-34. DOI: 10.1517/14728220802705696. View

Ros S, Santos C, Moco S, Baenke F, Kelly G, Howell M . Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov. 2012; 2(4):328-43. DOI: 10.1158/2159-8290.CD-11-0234. View

10.

Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J . Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138(2):245-56. PMC: 2726827. DOI: 10.1016/j.cell.2009.04.056. View

11.

Hu R, Isaacs W, Luo J . A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate. 2011; 71(15):1656-67. PMC: 3360954. DOI: 10.1002/pros.21382. View

12.

Memarzadeh S, Xin L, Mulholland D, Mansukhani A, Wu H, Teitell M . Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell. 2007; 12(6):572-85. PMC: 2931420. DOI: 10.1016/j.ccr.2007.11.002. View

13.

Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

14.

Cai C, He H, Chen S, Coleman I, Wang H, Fang Z . Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011; 20(4):457-71. PMC: 3225024. DOI: 10.1016/j.ccr.2011.09.001. View

15.

Gao H, Ouyang X, Banach-Petrosky W, Shen M, Abate-Shen C . Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res. 2006; 66(16):7929-33. DOI: 10.1158/0008-5472.CAN-06-1637. View

16.

Higano C, Schellhammer P, Small E, Burch P, Nemunaitis J, Yuh L . Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16):3670-9. DOI: 10.1002/cncr.24429. View

17.

Bakin R, Gioeli D, Bissonette E, Weber M . Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res. 2003; 63(8):1975-80. View

18.

Haapala K, Hyytinen E, Roiha M, Laurila M, Rantala I, Helin H . Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest. 2001; 81(12):1647-51. DOI: 10.1038/labinvest.3780378. View

19.

Kypta R, Waxman J . Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 2012; 9(8):418-28. DOI: 10.1038/nrurol.2012.116. View

20.

Bernard D, Pourtier-Manzanedo A, Gil J, Beach D . Myc confers androgen-independent prostate cancer cell growth. J Clin Invest. 2003; 112(11):1724-31. PMC: 281646. DOI: 10.1172/JCI19035. View